
    
      The neovascular age related macular degeneration(AMD) is a important cause of legal blindness
      in adults older than 50 years. Currently the treatment is photodynamic therapy that offer
      stabilization and limited visual improvement after 2 years of therapy. Bevacizumab has been
      reported effective used as intravenous injection for AMD. But serious side effects have been
      reported with the use of this drug in oncologic patients. The intravitreal use has been
      reported in limited case reports and safety and efficacy should be determined. The purpose of
      this study is efficacy and safety of 2.5 mg intravitreal of bevacizumab for AMD 4 days after
      photodynamic therapy with verteporfin
    
  